Next generation clonal neoantigen targeting T cells, generated using the PELEUS (TM) bioinformatics platform and the VELOS (TM) manufacturing method show superior reactivity and phenotypic characteristics than classical TIL products
Eleni Kotsiou, Katy Newton, Sonal Varsani, Tz Hou, SA Quezada, Samra Turajlic(Royal Marsden NHS Foundation Trust), Mariam Jamal‐Hanjani(CRUK Lung Cancer Centre of Excellence), Pablo D. Becker(United Therapeutics (United Kingdom)), Theres Oakes(University College London), James L. Reading(CRUK Lung Cancer Centre of Excellence), Andrew W. Craig(Queen's University), Jennine Mootien, Farah Islam(London Cancer), Edward Samuel, Andrew R. Haynes(Mary Lyon Centre at MRC Harwell), S. Patel, Lyra Del Rosario(Royal Marsden NHS Foundation Trust), Jane Robertson(Cancer Research UK), Martin D. Foster(Churchill Hospital), Jean B. Robinson(The Honourable Society of Lincoln's Inn), David Lawrence(South Australia Pathology)
UCL Discovery (University College London)
August 1, 2020
Cited by 0
Related Papers
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Resolving genetic heterogeneity in cancer
|Nature Reviews Genetics|2019|689